Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Retatrutide structure

Retatrutide

Metabolic
Phase 2 Research
40%
Low-Moderate Risk
2/5

Warnings

Investigational - not FDA approved
Similar warnings expected as other GLP-1 agonists

Contraindications

PregnancyBreastfeedingPersonal Or Family History MTCMEN2 SyndromePancreatitis History

Drug Interactions

InsulinSulfonylureas

Possible Side Effects

NauseaDiarrheaVomitingConstipationDecreased Appetite

Legal & Regulatory

FDA Status Research Only
WADA Status Not Prohibited
Prescription Required

Pregnancy

Category X - Contraindicated